Completed NCT01714713
This study is completed in the United States, in Australia, in Canada, .... It is testing EVP-6124 (Alpha-7 nAChR) for schizophrenia.
Multiple locations, including Little Rock Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug i A study involving a medication or substance. From 18 Years to 50 Years
Countries United States, Australia, Canada, ...
Sponsor FORUM Pharmaceuticals Inc
Condition Schizophrenia Completed NCT00642369
This study is completed in China. It is testing quetiapine for schizophrenia.
In Guangzhou Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 65 Years
Countries China
Sponsor Guang Dong Provincial Mental Health Institute
Condition Schizophrenia Completed NCT00645307
This study is completed. It is testing Paliperidone ER for schizophrenia.
Location not clearly listed Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug Over 18 Years
Countries
Sponsor Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition Schizophrenia Completed NCT00668837
This study is completed. It focuses on Schizophrenia.
Location not clearly listed Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 65 Years
Countries
Sponsor Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition Schizophrenia Completed NCT00650793
This study is completed. It is testing Paliperidone ER for schizophrenia.
Location not clearly listed Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug Over 18 Years
Countries
Sponsor Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition Schizophrenia Completed NCT00645099
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Buenos Aires Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 65 Years
Countries France, Argentina, Egypt, ...
Sponsor Janssen-Cilag International NV
Condition Schizophrenia Completed NCT02880462
This study is completed. It is testing Sulforaphane add-on Effects for schizophrenia.
Location not clearly listed Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Other From 18 Years to 50 Years
Countries
Sponsor Central South University
Condition Schizophrenia Withdrawn NCT00743847
This study was withdrawn. It focuses on schizophrenia.
Location not clearly listed Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 55 Years
Countries
Sponsor Pfizer
Condition Schizophrenia Completed NCT01942382
This summary needs review. Please check the official study record and contact the research team for details.
Location not clearly listed Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 20 Years to 65 Years
Countries
Sponsor Janssen Pharmaceutical K.K.
Condition Schizophrenia Completed NCT04118127
This summary needs review. Please check the official study record and contact the research team for details.
In Tokyo Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 64 Years
Countries Japan
Sponsor Otsuka Pharmaceutical Co., Ltd.
Condition Schizophrenia Completed NCT03425552
This study is completed in Jordan. It is testing Bioavailability Between Two Products Containing Paliperidone 100 mg for schizophrenia.
Multiple locations, including Amman Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 65 Years
Countries Jordan
Sponsor Pharmathen S.A.
Condition Schizophrenia Completed NCT02002832
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Beijing Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 65 Years
Countries China
Sponsor Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Condition Schizophrenia